7 employees
Alveolus Bio is pursuing the development of novel FDA-approved therapeutics to address chronic respiratory illnesses.
2020
$2.5M
from 2 investors over 2 rounds
Alveolus Bio raised undisclosed on August 9, 2023
Investors: Innovate Alabama
Alveolus Bio raised $2.5M on February 15, 2023
Investors: National Heart, Lung, and Blood Institute